Nu-Med Plus, Inc.
Nu-Med Plus, Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Related Party | - | 0 | 0 | 0 | 0 | - | 0 | - | |||||
Assets | |||||||||||||
Assets Current | |||||||||||||
Cash And Cash Equivalents At Carrying Value | - | - | - | 0 | 0 | - | 0 | 0 | |||||
Cash | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | |||||
Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Long Term Assets | |||||||||||||
Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Noncurrent | |||||||||||||
Property Plant And Equipment Net | - | 0 | - | - | - | - | - | - | |||||
Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities And Stockhold… | |||||||||||||
Liabilities Current | |||||||||||||
Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Long Term Liabilities | |||||||||||||
Long Term Debt Noncurrent | 0 | 0 | - | - | - | - | - | - | |||||
Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Commitments And Contingencies | 0 | - | - | - | - | - | - | - | |||||
Stockholders Equity | |||||||||||||
Preferred Stock Value | 0 | 0 | - | - | - | - | - | - | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Retained Earnings Accumulated Deficit | -10 | -10 | -10 | -10 | -10 | -10 | -10 | -10 | |||||
Stockholders Equity | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | - | - | 0 | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | - | - | 0 | - | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | |||||
Common Stock Shares Issued | 84 | 84 | 84 | 84 | 84 | 84 | 84 | 81 | |||||
Shares Outstanding | 84 | 84 | 84 | 84 | 84 | 84 | 84 | 81 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -33.07% | 5.64% | 20.73% | - | - | - | - | - | - | - | - | - |
| 2025 | - | - | - | - | - | - | - | - | - | 17.23% | -21.54% | 23.85% |
| 2024 | 4.11% | 16.58% | 4.95% | - | - | - | 0.96% | -18.44% | -25.08% | -42.53% | -40.23% | -45.98% |
| 2023 | - | - | - | - | - | - | 0.00% | 119.84% | 84.21% | -5.00% | -31.06% | -14.29% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Nu-Med Plus, Inc. (NUMD) — SEC Financial Statements & Analysis
Nu-Med Plus, Inc. (NUMD) is a surgical & medical instruments & apparatus company, incorporated in UT. Nu-Med Plus, Inc. trades on OTC as: NUMD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Nu-Med Plus, Inc. reported a Debt-to-Equity ratio of -1.05x, a Price-to-Book (P/B) ratio of -3.62x (TTM), at a market cap of $967.49K. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.05x
- P/B TTM
- -3.62x
- Market Cap
- $967.49K
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Nu-Med Plus, Inc. in?
Nu-Med Plus, Inc. (NUMD) operates in the Surgical & Medical Instruments & Apparatus industry.
What is NUMD's market cap?
Nu-Med Plus, Inc. (NUMD) has a market capitalization of $967.49K as of 2026-06-30.
What exchange does NUMD trade on?
Nu-Med Plus, Inc. (NUMD) trades on the OTC.
Where is Nu-Med Plus, Inc. incorporated?
Nu-Med Plus, Inc. is incorporated in UT.